TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of U=U Messaging on HIV in South Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men at least 18 years of age within the vicinity of the mobile Tutu Tester HIV testing mobile clinic~Exclusion Criteria:~* None

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard of care messaging (Type: EXPERIMENTAL): On mobile clinic days randomized to standard of care messaging, participants will receive standard invitation cards distributed at the Tutu Tester containing basic information encouraging HIV testing. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the standard invitation card and share a brief script including the standard Tutu Tester message that free HIV testing is available at the Tutu Tester, with no further information or motivation to test.
- U=U messaging (Type: EXPERIMENTAL): On mobile clinic days randomized to U=U messaging, participants will receive the U=U invitation cards distributed at the Tutu Tester that will seek to assuage the fears of testing HIV positive by conveying the message that HIV treatment makes it possible for HIV positive people to be untransmittable and to live normal lives. Messages will encourage men to come in for HIV testing at the mobile clinic on the same day. A mobile clinic recruiter will deliver the U=U invitation card and share a brief script asking people if they knew they could control HIV and that pills exist that can keep them healthy and ensure they don't transmit the virus to their sex partners, and that free HIV testing is available at the Tutu Tester.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Voluntary signed informed consent (IC)~* Pathologically proven diagnosis of any of the following malignancies:~  * Small cell lung cancer (SCLC).~ * Head and neck carcinoma (H\&N). Salivary glands tumors are excluded.~ * Neuroendocrine tumors (NETs), grade 2 and grade 3 according to World Health Organization classification.~ * Biliary tract carcinoma.~ * Endometrial carcinoma.~ * BRCA 1/2- associated metastatic breast carcinoma~ * Carcinoma of unknown primary site.~ * Germ cell tumor (GCTs), excluding immature teratoma, or teratoma with malignant transformation.~ * Ewing's family of tumors (EFTs)~* Prior treatment. Patients must have received:~  * SCLC, endometrial carcinoma: one prior chemotherapy-containing line.~ * H\&N, NETs, biliary tract, CUP: one or two prior chemotherapy-containing lines~ * GCTs: no limit of prior therapy~ * EFTs: no more than two prior chemotherapy-containing lines in the metastatic/recurrent setting.~ * BRCA 1/2-associated metastatic breast carcinoma: at least one but no more than three prior chemotherapy-containing lines.~* Performance status ≤ 2 \[Eastern Cooperative Oncology Group (ECOG)\]~* Adequate major organ function~* At least three weeks since the last chemotherapy~* Women of childbearing potential must have pregnancy excluded by appropriate testing before study entry~Exclusion Criteria:~* Prior treatment with PM01183 or trabectedin~* Prior or concurrent malignant disease unless in complete remission for more than five years~* Known central nervous system (CNS) involvement~* Relevant diseases or clinical situations which may increase the patient's risk~* Pregnant or breastfeeding women and fertile patients (men and women) who are not using an effective method of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lurbinectedin (PM01183) (Type: EXPERIMENTAL): lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tanezumab In Osteoarthritis Of The Knee (2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the knee according to Kellgren-Lawrence x-ray grade of 2~Exclusion Criteria:~* Pregnancy or intent to become pregnant~* BMI greater than 39~* other severe pain, significant cardiac, neurologic or cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Males and females between the ages of 18 and 75 who are diagnosed with moderate to severe Crohn's Disease defined by a CDAI score of \>= 220 and \<= 450, normal laboratory parameters,~* are willing and able to give informed consent, and~* are able to self-inject or have a designee or healthcare professional who can inject the study medication.~Exclusion:~* History of certain types of cancer, diagnosis of ulcerative colitis,~* female or breast feeding subjects,~* surgical bowel resection(s) with in the past 6 months,~* history of listeria,~* human immunodeficiency virus (HIV),~* central nervous system demyelinating disease or untreated TB,~* history of a poorly controlled medical condition,~* unsuccessful response to infliximab or any anti-TNF agent use in the past.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In-patients or out-patients with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology~* Have surgically or medically castrated, with testosterone levels of less than 50 nanogram per deciliter~* Have Prostate Specific Antigen (PSA) level of at least 5 nanogram per milliliter~* Be under PSA progression according to Prostate-Specific Antigen Working Group (PSAWG) eligibility criteria or objective progression by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 criteria for participants with measurable disease after androgen deprivation~* Have been used at least 1 but not more than 2 cytotoxic chemotherapy regimens for Metastatic Castration-Resistant Prostate Cancer (mCRPC). At least 1 regimen must have contained docetaxel. If docetaxel-containing chemotherapy was used more than once, those of regimens containing docetaxel would be considered as 1 regimen in total~Exclusion Criteria:~* Has received other hormonal therapy, including any dose of finasteride, dutasteride, any herbal product known to decrease PSA levels or any systemic corticosteroid within 4 weeks prior to Cycle 1 Day 1 or has received ketoconazole for prostate cancer~* Has received radiotherapy, chemotherapy (including estramustine) or immunotherapy (including provenge) within 4 weeks, or single fraction of palliative radiotherapy within 2 weeks prior to Cycle 1 Day 1~* Has had surgery or local prostatic intervention within 4 weeks prior to Cycle 1 Day 1. In addition, any clinically relevant sequel from the surgery must have resolved prior to Cycle 1 Day 1~* Has clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events, severe or unstable angina, or New York Heart Association (NYHA) Class 3 to 4 heart disease or cardiac ejection fraction measurement of less than 50 percent within 6 months prior to Cycle 1 Day 1~* Has uncontrolled hypertension (systolic blood pressure greater than or equal to 160 millimeter of mercury or diastolic blood pressure greater than or equal to 95 millimeter of mercury)

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abiraterone (Type: EXPERIMENTAL): Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ductal carcinoma in situ (DCIS) or stage I breast cancer by stereotactic core or incisional biopsy~* Planning to undergo surgery in 3-6 weeks~  * Patients undergoing re-excision due to evidence of tumor present at surgical margins are eligible~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Female~* Menopausal status not specified~* ALT and AST ≤ 10% above upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to tolerate statins~* Willing to undergo 2 blood draws (separated by approximately 3-4 weeks) during study participation (control arm)~PRIOR CONCURRENT THERAPY:~* No other concurrent statins~* No concurrent chemotherapy~* No concurrent administration of any of the following:~  * Niacin~ * Propranolol~ * Cholestyramine~ * Cyclosporine~ * Digoxin~ * Erythromycin~ * Itraconazole~ * Gemfibrozil~ * Phenytoin~ * Diclofenac~ * Tolbutamide~ * Glyburide~ * Losartan~ * Cimetidine~ * Ranitidine~ * Omeprazole~ * Rifampin~ * Warfarin~* No initiation of new hormonal therapy during study participation~* Concurrent participation in other clinical trials (e.g., for DCIS or prevention) is allowed

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive oral fluvastatin sodium as in arm I at a higher dose.
- Arm III (Type: EXPERIMENTAL): Patients do not receive fluvastatin sodium. breast Cancer surgery only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients, age 18-75 yrs.~* COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 ≥92% at 750 m.~* Born, raised and currently living at low altitude (\<800m).~* Written informed consent.~Exclusion Criteria:~* COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1/FVC \<0.7, FEV1 \<40% predicted, oxygen saturation on room air \<92% at 750 m).~* Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke; OSA; pneumothorax in the last 2 months.~* Internal, neurologic, rheumatologic or psychiatric disease including current heavy smoking (\>20 cigarettes per day)~* Known renal failure or allergy to acetazolamide and other sulfonamides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ACETAZOLAMIDE oral capsule (Type: ACTIVE_COMPARATOR): Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
- PLACEBO oral capsule (Type: PLACEBO_COMPARATOR): Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older infected with HIV and weigh at least 40 kg.~* Plasma HIV RNA viral load of 1000 copies/mL or greater and CD4 count of 100 cells/mL or greater~* Be willing to use two forms of contraception throughout study~* No previous exposure to antiretroviral (ARV) drugs~Exclusion Criteria:~* Pregnancy or breastfeeding~* Physical or psychiatric disability~* Proven or suspected acute hepatitis within 30 days prior to study entry~* Active AIDS-defining opportunistic infection or disease~* History of acute or chronic pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Posterior spinal surgery~2. Age ≥ 65 years~3. American Society of Anesthesiologists (ASA) grade I-III~Exclusion Criteria:~1. Inability to obtain written informed consent~2. Allergy to rocuronium or anesthetic agents used in the protocol~3. Known or suspected neuromuscular disorders~4. Significant renal disease with a serum creatinine ≥ 2 mg/dl~5. Significant liver disease~6. A family history of malignant hyperthermia

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex group (Type: EXPERIMENTAL): 2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
- Neostigmine group (Type: ACTIVE_COMPARATOR): 50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.~Dosing will be based on actual body weight not ideal body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Programmed Intermittent Epidural Bolus Time Interval and Injection Volume

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* nulliparous women~* term gestation (greater than or equal to 37 weeks gestation)~* spontaneous labor or with spontaneous rupture of membranes~Exclusion Criteria:~* Systemic disease (e.g., diabetes mellitus, hypertension, preeclampsia)~* use of chronic analgesic medications~* systemic opioid labor analgesia prior to the initiation of neuraxial labor analgesia~* cervical dilation less than 2cm or greater than 5cm at time of initiation of neuraxial analgesia~* delivery within 90 minutes of intrathecal injection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 2.5 mL bolused every 15 minutes (Type: ACTIVE_COMPARATOR): None
- 5ml bolused every 30 minutes (Type: ACTIVE_COMPARATOR): None
- 10ml bolused every 60 minutes (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Epilepsy with partial seizures~Exclusion Criteria:~* Subject received SPM 927 in a previous trial

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hybrid Collaborative Care Randomized Program Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~At least three visits to the General Mental Health Clinic's BHIP team in prior year~Exclusion Criteria:~Chart evidence of dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Implementation Facilitation (Type: EXPERIMENTAL): Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
- Educational Materials (Type: PLACEBO_COMPARATOR): Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Male or female between 18 and 75 years of age, inclusive~2. Diagnosis of OSA according to ICSD-3 criteria~3. Body mass index from 18 to \<45 kg/m2~4. Consent to use a medically acceptable method of contraception~5. Willing and able to provide written informed consent~Major Exclusion Criteria:~1. Female subjects who are pregnant, nursing, or lactating.~2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness~3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria~4. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy or safety assessments or the ability of the subject to complete the trial per the judgment of the principal investigator~5. History of bariatric surgery within the past year or a history of any gastric bypass procedure~6. Presence or history of significant cardiovascular disease~7. Use of any over the counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness~8. Received an investigational drug in the past 30 days or five half-lives (whichever is longer)~9. Previous exposure to or participation in a clinical trial of JZP-110 (ADX-N05, R228060, or YKP10A)~10. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 75, 150, 300 mg of JZP-110 (Type: ACTIVE_COMPARATOR): Once Daily Dosing
- Placebo (Type: ACTIVE_COMPARATOR): Once Daily Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete